Related Experiment Video
Updated: May 27, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines
1School of Engineering and Applied Sciences, and Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02138.
Abstract:
Therapeutic cancer vaccines are emerging as novel and potent approaches to treat cancer. These vaccines enhance the body's immune response to cancerous cells, and dendritic cells (DCs), an initiator of adaptive immunity, are a key cell type targeted by these strategies. Current DC-based cancer vaccines are based on ex vivo manipulation of the cells following their isolation from the patient, followed by reintroduction to the patient, but this approach has many limitations in practical cancer treatment. However, recent progress in materials science has allowed the design and fabrication of physically and chemically functionalized materials platforms that can specifically target DCs in the body. These materials, through their in vivo modulation of DCs, have tremendous potentials as new cancer therapies. Nanoparticles, which are several orders of magnitude smaller than DCs, can efficiently deliver antigen and danger signals to these cells through passive or active targeting. Three-dimensional biomaterials, with sizes several orders of magnitude larger than DCs, create microenvironments that allow the effective recruitment and programming of these cells, and can be used as local depots of nanoparticles targeting resident DCs. Both material strategies have shown potential in promoting antigen-specific T cell responses of magnitudes relevant to treating cancer.
Insights
Materials science innovations offer new ways to create cancer vaccines. Nanoparticles and 3D biomaterials can target dendritic cells (DCs) in the body, enhancing immune responses against cancer more effectively than current methods.
Area of Science:
- Immunology
- Materials Science
- Oncology
Background:
- Therapeutic cancer vaccines aim to boost the immune system against cancer.
- Dendritic cells (DCs) are crucial for initiating adaptive immunity and are key targets for cancer vaccines.
- Current DC-based vaccines require ex vivo cell manipulation, posing practical limitations.
Purpose of the Study:
- To explore the potential of materials science in developing novel in vivo dendritic cell-targeting cancer vaccines.
- To investigate how nanoparticles and 3D biomaterials can be used to modulate DCs for cancer therapy.
Main Methods:
- Designing and fabricating physically and chemically functionalized materials platforms.
- Utilizing nanoparticles for efficient antigen and danger signal delivery to DCs.
- Employing 3D biomaterials to create microenvironments for DC recruitment and programming.
Main Results:
- Materials platforms can specifically target DCs in vivo.
- Nanoparticles enable targeted delivery of therapeutic payloads to DCs.
- 3D biomaterials serve as depots for nanoparticles and recruit resident DCs.
- Both strategies show potential in promoting antigen-specific T cell responses relevant to cancer treatment.
Conclusions:
- Materials science advancements enable the development of in vivo DC-targeting cancer vaccines.
- Nanoparticles and 3D biomaterials represent promising strategies for next-generation cancer immunotherapies.
- These novel approaches overcome limitations of traditional ex vivo DC-based vaccines.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy